Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In West To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in West between February 16, 2023, and February 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, June 6, 2025 /PRNewswire/ -- Faruqi & Faruqi, ...

Core Viewpoint - A class action securities lawsuit has been filed against West Pharmaceutical Services, Inc. alleging securities fraud that negatively impacted investors between February 16, 2023, and February 12, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that West Pharmaceutical Services made false statements regarding customer demand and attributed challenges to temporary COVID-related product destocking, while in reality, the company was facing significant ongoing destocking in its high-margin HVP portfolio [3]. - It is alleged that the SmartDose device, which was marketed as a high-margin growth product, actually diluted the company's profit margins due to operational inefficiencies [3]. - The margin pressures from these issues raised the risk of costly restructuring activities, including the company's exit from continuous glucose monitoring contracts with long-standing customers [3]. - As a result of these factors, the positive statements made by the defendants about the company's business and prospects were materially false or misleading [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified time frame have until July 7, 2025, to request to be appointed as lead plaintiff in the case [4]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members, and there is no obligation to participate [4]. Group 3: Law Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

West Pharmaceutical Services, Inc. Eric M. Green President, CEO and Chair of the Board William Blair 45th Annual Growth Stock Conference June 5, 2025 Safe Harbor Statement Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about product develop ...

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of the July 7, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of investors who acquired West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE:WST) securities during the period from February 16, 2023, through February 12, 2025 (“the Class Period”). [LEARN MORE ABOUT THE CLASS ACTION] On February 13, 2025, when West issued extremely weak 2025 r ...

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the “Class Period”), of the important July 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased West common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fe ...

WHAT'S NEXT? If you suffered a loss in West Pharmaceutical Services, Inc. during the relevant time frame, you have until July 7, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Levi & Ko ...

West Pharmaceutical Services (WST) FY Conference June 05, 2025 11:40 AM ET Speaker0 Okay. Thank you, everyone, for sticking with us here on Thursday and joining us for the WES management presentation. My name is Matt Larue. I cover WES and and life science tool space here at William Blair. Very pleased to have WES CEO, Eric Green, here with us today and John Sweeney from investor relations. So thank you both for for being here. Two quick things. The breakout is in the Maher Room. You can join us there after ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In West To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in West between February 16, 2023, and February 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Faruqi & ...

LOS ANGELES, June 02, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming July 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) common stock between February 16, 2023 and February 12, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR WEST INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING ...

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ("West Pharmaceutical Services, Inc." or the "Company") (NYSE: WST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a ...